AEON Biopharma (AEON) Registration filing summary

Company overview and business model

• Focuses on developing ABP-450 as a biosimilar to BOTOX® for therapeutic indications, aiming for full-label alignment and seamless substitution for prescribers and payers.

• Holds exclusive development and commercialization rights for ABP-450 in the US, Canada, EU, UK, and select international territories.

• ABP-450 is manufactured by Daewoong Pharmaceutical in cGMP-compliant facilities and is already approved for aesthetic use in several markets.

• Strategy targets the $3.5 billion US therapeutic botulinum toxin market, projected to grow at 8% annually.

• Plans to pursue regulatory approval via the Section 351(k) biosimilar pathway for therapeutic indications only.

Financial performance and metrics

• As of March 31, 2026, had an accumulated deficit of $482.6 million and has never generated revenue from ABP-450.

• Concluded it does not have sufficient cash to fund operations through March 31, 2027 without additional financing.

• Expects to have sufficient cash to fund operations into Q3 2026; further development will require additional funding.

• Net proceeds from the offering are estimated at $11.0 million, or $12.8 million if the over-allotment option is fully exercised.

Use of proceeds and capital allocation

• Net proceeds will be used for working capital and general corporate purposes, including comparative analytical testing on ABP-450 to support biosimilarity with BOTOX®.

• Management has broad discretion over use of proceeds and may allocate funds to other purposes as needed.

• May use a portion of proceeds for acquisitions or investments in complementary businesses or technologies.